{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:16:24Z","timestamp":1791476184069,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejphar.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T17:46:31Z","timestamp":1528220791000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":286,"special_numbering":"C","title":["AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions"],"prefix":"10.1016","volume":"833","author":[{"given":"Davoud","family":"Sanajou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ghorbani Haghjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Argani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Aslani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.06.001_bib1","first-page":"1002","article-title":"Targeted regulation of PI3K\/Akt\/mTOR\/NF-\u03baB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy","volume":"13","author":"Ahmad","year":"2013","journal-title":"Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"10.1016\/j.ejphar.2018.06.001_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.dsx.2015.02.008","article-title":"Management of diabetic nephropathy: recent progress and future perspective","volume":"9","author":"Ahmad","year":"2015","journal-title":"Diabetes Metab. Syndr.: Clin. Res. Rev."},{"key":"10.1016\/j.ejphar.2018.06.001_bib3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib4","article-title":"The receptor for advanced glycation endproducts mediates podocyte heparanase expression through NF-\u03baB signaling pathway","author":"An","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib5","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.06.001_bib6","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/j.amjhyper.2004.08.022","article-title":"Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process","volume":"17","author":"Bakris","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.06.001_bib7","first-page":"1699","article-title":"Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues","volume":"143","author":"Brett","year":"1993","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.15585\/mmwr.mm6643a2","article-title":"Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes\u2014United States and Puerto Rico, 2000\u20132014","volume":"66","author":"Burrows","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ejphar.2018.06.001_bib9","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1159\/000148209","article-title":"Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes","volume":"28","author":"Chen","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1681\/ASN.2009010018","article-title":"Advanced glycation end-products induce tubular CTGF via TGF-\u03b2-independent Smad3 signaling","volume":"21","author":"Chung","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib11","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1038\/sj.ki.5002387","article-title":"Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes","volume":"72","author":"Coughlan","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.06.001_bib12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1172\/JCI58642","article-title":"A multimodal RAGE-specific inhibitor reduces amyloid \u03b2\u2013mediated brain disorder in a mouse model of Alzheimer disease","volume":"122","author":"Deane","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.06.001_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1523-1755.2002.00207.x","article-title":"Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat","volume":"61","author":"Degenhardt","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.06.001_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00125-008-0935-x","article-title":"LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat","volume":"51","author":"Figarola","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2018.06.001_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00125-003-1162-0","article-title":"LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats","volume":"46","author":"Figarola","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2018.06.001_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.53.1.166","article-title":"Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice","volume":"53","author":"Flyvbjerg","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.06.001_bib18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","article-title":"Clinical trial of an inhibitor of RAGE-A\u03b2 interactions in Alzheimer disease","volume":"82","author":"Galasko","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2018.06.001_bib19","doi-asserted-by":"crossref","first-page":"8795","DOI":"10.1038\/s41598-017-09257-3","article-title":"Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation","volume":"7","author":"Gasparotto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.06.001_bib20","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2016","journal-title":"J. Nephropharmacol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2337\/db13-0316","article-title":"Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice","volume":"63","author":"Giacco","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib22","first-page":"db170538","article-title":"RAGE deletion confers renoprotection by reducing responsiveness to transforming growth factor-\u03b2 and increasing resistance to apoptosis","author":"Hagiwara","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13020-017-0134-0","article-title":"Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K\/Akt-mediated NF-\u03baB pathways in KK-Ay mice","volume":"12","author":"Hong","year":"2017","journal-title":"Chin. Med."},{"key":"10.1016\/j.ejphar.2018.06.001_bib24","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1159\/000486154","article-title":"Salvianolic acid A protects against diabetic nephropathy through ameliorating glomerular endothelial dysfunction via inhibiting AGE-RAGE signaling","volume":"44","author":"Hou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2018.06.001_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1677\/joe.1.06524","article-title":"Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice","volume":"188","author":"Jensen","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fendo.2013.00007","article-title":"Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis","volume":"4","author":"Kanasaki","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib27","doi-asserted-by":"crossref","DOI":"10.1042\/bst0311423","article-title":"Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats","author":"Karachalias","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejphar.2018.06.001_bib28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2018.06.001_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11357-009-9124-1","article-title":"Kaempferol modulates pro-inflammatory NF-\u03baB activation by suppressing advanced glycation endproducts-induced NADPH oxidase","volume":"32","author":"Kim","year":"2010","journal-title":"Age"},{"key":"10.1016\/j.ejphar.2018.06.001_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3904\/kjim.2016.219","article-title":"Treatment of diabetic kidney disease: current and future targets","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.ejphar.2018.06.001_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fphys.2012.00292","article-title":"Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling","volume":"3","author":"Kranstuber","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/01.ASN.0000133025.23732.46","article-title":"Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products","volume":"15","author":"Lassila","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5808\/GI.2013.11.4.224","article-title":"Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases","volume":"11","author":"Lee","year":"2013","journal-title":"Genom. Inform."},{"key":"10.1016\/j.ejphar.2018.06.001_bib34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199109193251202","article-title":"Advanced glycosylation end products in patients with diabetic nephropathy","volume":"325","author":"Makita","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.06.001_bib35","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db16-1281","article-title":"RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy","volume":"66","author":"Matsui","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.6779377","article-title":"Nonenzymatic browning in vivo: possible process for aging of long-lived proteins","volume":"211","author":"Monnier","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2018.06.001_bib37","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1038\/srep08931","article-title":"The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes","volume":"5","author":"Mulrennan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.06.001_bib38","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2337\/db06-0221","article-title":"RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin","volume":"55","author":"Myint","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2337\/diab.46.5.895","article-title":"Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation","volume":"46","author":"Nakamura","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib40","doi-asserted-by":"crossref","first-page":"e0147329","DOI":"10.1371\/journal.pone.0147329","article-title":"The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review","volume":"11","author":"Narres","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.06.001_bib41","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","article-title":"Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins","volume":"267","author":"Neeper","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.06.001_bib42","first-page":"32","article-title":"Maillard reactions in pharmaceutical formulations and human health","volume":"15","author":"Newton","year":"2011","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.ejphar.2018.06.001_bib43","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejphar.2018.06.001_bib44","first-page":"2017","article-title":"Classification and differential diagnosis of diabetic nephropathy","author":"Qi","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2018.06.001_bib45","article-title":"Glyoxalase 1 modulation in obesity and diabetes","author":"Rabbani","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ejphar.2018.06.001_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12013-007-0021-x","article-title":"Novel inhibitors of glycation and AGE formation","volume":"48","author":"Rahbar","year":"2007","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2018.06.001_bib47","doi-asserted-by":"crossref","first-page":"16R","DOI":"10.1093\/glycob\/cwi053","article-title":"Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation","volume":"15","author":"Ramasamy","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejphar.2018.06.001_bib48","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2337\/db09-1766","article-title":"Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse","volume":"59","author":"Reiniger","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000324939","article-title":"Clinical manifestation and natural history of diabetic nephropathy, diabetes and the kidney","author":"Ritz","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2478\/s11658-014-0205-5","article-title":"The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach","volume":"19","author":"Salahuddin","year":"2014","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejphar.2018.06.001_bib51","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1681\/ASN.2010020218","article-title":"NF-\u03baB in renal inflammation","volume":"21","author":"Sanz","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2337\/dc16-1875","article-title":"Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study","volume":"40","author":"Saremi","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2018.06.001_bib53","article-title":"Contribution of myo-inositol oxygenase in AGE:RAGE-mediated renal tubulointerstitial injury in the context of diabetic nephropathy","author":"Sharma","year":"2017","journal-title":"Am. J. Physiol.-Ren. Physiol. ajprenal"},{"key":"10.1016\/j.ejphar.2018.06.001_bib54","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2337\/diab.40.10.1328","article-title":"Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat","volume":"40","author":"Soulis-Liparota","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","article-title":"Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms","volume":"3","author":"Stirban","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ejphar.2018.06.001_bib56","doi-asserted-by":"crossref","first-page":"F763","DOI":"10.1152\/ajprenal.00591.2009","article-title":"Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy","volume":"298","author":"Tan","year":"2009","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1440-1797.2010.01437.x","article-title":"Differential effects of advanced glycation end\u2010products on renal tubular cell inflammation","volume":"16","author":"Tang","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.ejphar.2018.06.001_bib58","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1681\/ASN.V1191656","article-title":"Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease","volume":"11","author":"Tanji","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/1389450054021873","article-title":"The role of AGEs and AGE inhibitors in diabetic cardiovascular disease","volume":"6","author":"Thomas","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2018.06.001_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","article-title":"Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts","volume":"419","author":"Thornalley","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2018.06.001_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ackd.2010.10.003","article-title":"Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management","volume":"18","author":"Van Buren","year":"2011","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.ejphar.2018.06.001_bib62","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2337\/db11-1546","article-title":"Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice","volume":"61","author":"Watson","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib63","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","article-title":"RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy","volume":"162","author":"Wendt","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2018.06.001_bib64","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.2337\/diabetes.51.11.3283","article-title":"ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat","volume":"51","author":"Wilkinson-Berka","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.06.001_bib65","doi-asserted-by":"crossref","first-page":"39349","DOI":"10.1074\/jbc.M302771200","article-title":"Phosphatidylinositol 3\u2032-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products","volume":"278","author":"Xu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.06.001_bib66","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2174\/156652407783220769","article-title":"RAGE in diabetic nephropathy","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejphar.2018.06.001_bib67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1172\/JCI11771","article-title":"Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice","volume":"108","author":"Yamamoto","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.06.001_bib68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ki.2015.331","article-title":"Kallistatin protects against diabetic nephropathy in db\/db mice by suppressing AGE-RAGE-induced oxidative stress","volume":"89","author":"Yiu","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.06.001_bib69","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918303194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918303194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T22:22:20Z","timestamp":1661379740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918303194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":69,"alternative-id":["S0014299918303194"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.06.001","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}